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Abstract 
Background and purpose: 
End stage renal disease (ESRD) requiring hemodialysis (HD) carries up to a 10-fold greater 
risk of stroke than normal renal function. Knowledge concerning risk factors and 
management strategies derived from the general population may not be applicable to those 
with ESRD. We studied a large ESRD population to identify risk factors and outcomes for 
stroke. 
Methods:    
All adult patients receiving HD for ESRD from 01/01/2007 to 31/12/2012 were extracted 
from the electronic patient record. Variables associated with stroke were identified by 
survival analysis; demographic, clinical, imaging and dialysis related variables were assessed 
and case-fatality determined. Follow-up was until 31/12/2013.  
Results  
1382 patients were identified (mean age 60.5 years, 58.5% male). The prevalence of AF was 
21.2% and 59.4% were incident HD patients. 160 (11.6%) experienced a stroke during 3471 
patient-years of follow-up (95% ischemic). Stroke incidence was 41.5/1000 patient-years in 
prevalent and 50.1/1000 patient-years in incident HD patients. Factors associated with stroke 
on regression analysis were prior stroke, diabetes and age at starting renal replacement 
therapy. AF was not significantly associated with stroke and warfarin did not affect stroke 
risk in warfarin treated patients.  Fatality was 18.8% at 7, 26.9% at 28 and 56.3% 365 days 
after stroke.  
Conclusions   
Incidence of stroke is high in patients with ESRD on HD with high case-fatality. Incident HD 
patients had the highest stroke incidence. Many, but not all, important risk factors commonly 
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associated with stroke in the general population were not associated with stroke in patients 
receiving HD. 
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Introduction 
The risk of stroke is 5-10 times greater in those with end stage renal disease(ESRD) on 
hemodialysis (HD) compared to patients with normal renal function[1]. However, risk factors 
for stroke in ESRD may differ compared to the general population. Atrial fibrillation(AF), for 
example, is associated with adverse outcomes in the ESRD population[2–5] but its influence 
on stroke risk is less clear. Moreover, warfarin use may not protect against stroke in patients 
with ESRD and AF[6]. Further, there is a temporary rise in stroke incidence following 
commencement of HD[7] suggesting that either commencement of dialysis itself or specific 
dialysis related variables increase stroke risk. For instance, in the general population it is 
recognised that diuretic induced potassium depletion is associated with stroke[8]. Finally, 
most data on stroke risk in ESRD originates from large US registry studies, or relatively 
small single centre studies with low absolute number of stroke events.  
We performed a contemporary study in a large dialysis centre in a population with a high 
background prevalence of vascular disease, to identify risk factors for stroke in HD. We 
hypothesised that 1) stroke risk would be high, with high case-fatality in patients treated with 
HD, 2) that some common traditional risk factors for stroke would not be associated with 
stroke risk (with a particular focus on AF and the effect of warfarin) and 3) that dialysis 
specific variables would be associated with stroke risk.  
 
Methods 
All adult HD patients attending Glasgow Renal and Transplant Unit for hospital HD between 
1st January 2007 and 31st December 2012 were identified using the electronic patient record 
(EPR), (Strathclyde Electronic Renal Patient Record, Vitalpulse, UK).  Cohort entry was 
recorded as 1st January 2007 in patients already receiving HD (prevalent HD patients) or from 
date of commencing HD as their first renal replacement therapy (RRT) modality for ESRD 
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(incident HD patients). Patients treated with HD for acute kidney injury were excluded. 
Clinical and demographic details at cohort entry were recorded including primary renal 
diagnosis, presence of diabetes, cardiovascular disease, cerebrovascular disease, AF and 
antithrombotic drug use. We also extracted pre and post-dialysis blood pressure, 
ultrafiltration volume, pre-dialysis serum albumin, adjusted calcium, phosphate, blood 
hemoglobin, pre and post-dialysis serum potassium and urea reduction ratio at 90 days. The 
value from 90-days post cohort entry was used. The EPR links to all radiology departments in 
the West of Scotland so we were able to review all reports of brain imaging (computed 
tomography or magnetic resonance imaging). 
 
Outcomes and definition of stroke 
The time to first stroke in patients receiving HD occurring after study inception was recorded. 
Stroke was defined from the EPR as either 1) a new clinical diagnosis of stroke recorded in 
the diagnostic timeline, 2) the presence of ischemic or hemorrhagic stroke on brain imaging 
associated with a clinical history of new neurological deficit or stroke, or 3) any of 
cerebrovascular disease, cerebrovascular accident, cerebral infarct, subarachnoid hemorrhage 
or intracerebral hemorrhage listed on death certificate as a primary or major contributory 
factor to a patient death. All events were reviewed by 2 independent clinicians (M.D.F., 
P.B.M.) with cases adjudicated by a third observer (P.C.T.) where disagreement arose. 
Subdural and extradural hemorrhage were excluded. The West of Scotland Ethics Committee 
officer waived the need for ethical committee review on the basis that this was analysis of 
routine clinical data. 
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Statistical analysis 
Follow up data were available to December 31st 2013. Patient follow up was censored at renal 
transplantation. Baseline demographics were compared using Student’s t-test, Mann-Whitney 
U test, Chi-square test or one-way ANOVA as appropriate. Kaplan-Meier survival analysis 
was performed for time to first stroke and for mortality in all patients. A multivariable Cox 
survival analysis was performed to identify significant independent risk factors for stroke. A 
backward stepwise regression model was applied to identify significantly influential variables 
as defined at a p <0.05 and those were re-entered into a multivariable cox regression analysis. 
Data were analysed using SPSS version 21 (IBM, Armonk, New York) and StataSE 13 
(Statacorp, College Station, Texas). 
 
Results 
A total of 1382 patients receiving HD were included. Of these, 59.4% were incident HD 
patients. The median RRT vintage was 1206 days (IQR 2222) in the prevalent patients. The 
mean age was 60.5 years, 58.5% were male and 21.2% had AF. 245 (17.7%) patients 
received a kidney transplant during follow up. Censoring for death or transplantation, median 
follow-up for the cohort was 2.1 (IQR 2.9) years.  
160 patients (11.6%) experienced a stroke event over 3471 patient-years of follow up (table 
1). 149 patients (93.1%) had brain imaging performed as part of diagnostic assessment, with 
the rest considered to have a clinical diagnosis of stroke based on the death certification or at 
post mortem examination. The majority (95%) of events were ischemic. Stroke incidence was 
41.5/1000 patient-years in prevalent HD patients and 50.1/1000 patient-years in patients 
incident to HD during the follow up period. Age-adjusted stroke rates (WHO world standard) 
are available online (supplemental tables I&II).  There were baseline differences between 
patients who suffered stroke and patients who did not (table 1). 
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Atrial fibrillation, warfarin, antiplatelet therapy and risk of stroke, intracerebral 
hemorrhage or death 
There was no increased in rate of stroke in patient with AF compared to no AF on survival 
analysis (Figure 1). AF was more common in patients who died (26.2% vs 14.2%, p<0.001 
supplementary figure I). The rate of stroke did not differ in AF patients treated with warfarin 
compared to AF patients who were not (14.4% vs. 11.4%, p=0.45, Figure 2).  
 
Survival analyses of variables associated with risk of stroke 
Multivariable regression analyses revealed that age at starting RRT, previous cerebrovascular 
disease, presence of diabetes and post dialysis serum potassium were significantly associated 
with the risk of stroke. Backward stepwise regression was applied to identify  significant 
variables (p<0.05) for use in the final cox regression model. This revealed a significant 
independent association for age, prior cerebrovascular disease and diabetes with stroke 
(model 1). Removing all cases with a prior history of cerebrovascular disease from the 
analyses revealed that age at starting RRT and diabetes were still associated with stroke 
(model 2).  
 
Outcome in patients following stroke 
Case fatality (death within 7 days) for all stroke was 18.8% (n=30) and 126 of 160 (78.8%) 
died during follow-up. Fatality was 26.9% at 28 days and 56.3% at 1 year. Fatality was 
higher in patients with hemorrhagic compared to ischemic stroke with 7, 28 and 365 day 
fatality of 62.5%, 87.5% and 100% for hemorrhage compared to 16.4, 23.7 and 53.9% for 
ischemia. Fatality rates were higher when those with prior cerebrovascular disease were 
removed with 7, 28 and 365 day fatality of 24, 34 and 72%.  
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Discussion 
In the general population stroke is common and a leading cause of disability[9] with firmly 
established risk factors. Although incidence, outcomes and risk factors are described in the 
ESRD population, most published data originate from the US or Japan and are not necessarily 
representative of the UK or European populations.  Amongst a large cohort of incident and 
prevalent HD patients in the west of Scotland we have described a high incidence of stroke 
events alongside stroke variables and fatality rates. Of note, we report a higher incidence of 
stroke in the incident dialysis population compared to the prevalent patients and, 
interestingly, no association between AF or warfarin use and stroke events.  
 
Stroke Incidence in hemodialysis 
We found a high unadjusted incidence of stroke in patients with ESRD (46.1/1000 patient-
years) in keeping with previous reports where it ranges from 17.3 – 49/1000 patient-
years[1,10–13] but higher than a recent report from a UK study (46.1 vs 17.3/1000 patient-
years)[12]. This could be explained by the differences in study methodology (they excluded 
stroke within the first 90 days of commencing dialysis and required neuroimaging to 
diagnose all stroke events) and geographical variation (Scotland has the higher prevalence of 
cardiovascular disease in the UK[14,15]). Incidence of stroke was higher in the incident 
compared to the prevalent HD patients (50.1 vs 41.5/1000 patient-years). The increase in  
stroke risk associated with dialysis initiation[7] has previously been described,  however we 
are the first to describe a difference in stroke rate between incident and prevalent HD groups 
within the same population.  We report fewer cases of hemorrhage than in previous reports – 
a finding which is not unexpected for a predominantly (92.6%) Caucasian population[16].  
Case fatality following stroke was high, with a markedly higher rate in hemorrhagic stroke, 
and higher in those who experience their first ever stroke. As expected, fatality in our dialysis 
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population is higher than the reported background fatality rates for stroke in Scotland (26.9% 
vs 15.9% at 28 days)[15] but in keeping with reported rates in ESRD (30d fatality of 17.9% 
in ischemic stroke and 53.4% for hemorrhagic stroke)[17]. 
 
Risk Factors for stroke 
Risk factors for stroke in the general population include increasing age, prior cardiovascular 
disease, diabetes, hypertension and AF[18]. We found older age, presence of diabetes, 
previous cerebrovascular disease, a lower diastolic blood pressure and higher post dialysis 
potassium were significantly associated with stroke in patients receiving HD. This effect of 
potassium contrasts with the general population where higher potassium levels are associated 
with a lower blood pressure and stroke risk[8,19] although the mechanism is unclear. As it 
was of clinical interest we looked at the association of post dialysis potassium on risk of 
stroke using a univariable cox proportional hazards model. In the absence of other covariates, 
post HD potassium was significantly associated with stroke, HR 1.4 (95% CI 1.03, 1.9). 
However, when other covariates identified by stepwise regression were added into the model 
post HD potassium was no longer associated with stroke (table 2). A higher serum potassium 
following dialysis is likely to represent underlying comorbidity. In our study the mitigation of 
potassium’s effect on stroke risk is likely to reflect an association with presence of diabetes 
Interestingly, whilst presence of AF at baseline was associated with a higher mortality, we 
found no association between the presence of AF or warfarin use and stroke. In our group, the 
presence of AF represents a marker of comorbidity and advanced age rather than a cause of 
mortality. HD favours the initiation of AF through rapid shifts in fluid and electrolytes 
(potassium) and episodes of AF are common during HD [20] Whilst HD induced AF may 
contribute to the increase in stroke risk observed in those initiating dialysis it must be 
acknowledged that patients are anti-coagulated during their dialysis sessions. Therefore, it is 
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possible that HD-related AF may carry a lower risk of stroke than AF in the general 
population.   
 
Anticoagulation in ESRD 
Use of dose adjusted warfarin is accepted as an effective treatment in reducing the risk of 
ischemic stroke[21] in non-valvular AF. However, we did not detect an effect of warfarin on 
stroke risk in our study. In recent years data has emerged suggesting that warfarin use is 
either not protective against ischemic stroke[22],  associated with an increase in hemorrhagic 
and ischemic stroke[4,13,23] or is associated with harm through bleeding in the 
haemodialysis population[6,22]. Guidelines reflect this uncertainty and either do not mention 
patients with ESRD or make no recommendation[24–26]. There is unease about using 
vitamin K antagonists in ESRD not only due to the increased risk of bleeding but also the 
association with vascular calcification inducing cardiovascular disease or 
calciphylaxis[27,28].  Unfortunately, no suitable alternative currently exists. Although 
recently developed new oral anti-coagulants (NOACS) have been shown to be non-inferior or 
superior to warfarin in patients with non-valvular AF[25,29]in the general population, 
patients with ESRD are excluded from such stroke prophylaxis trials. Presently, NOACS are 
not recommended in those with a GFR <30ml/min[25].  
 
Limitations 
We report a single centre study and have described the clinical behaviour of stroke disease in 
1382 HD patients over 3471 years of patient follow-up. This is one of the largest single 
centre studies ever reported. We do however, recognised the following limitations. Due to the 
observational nature of our cohort we can only describe associations and not causation. 
Despite the size of this study the relatively low numbers of stroke events limit our ability to 
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detect risk factors associated with death within the stroke group. We acknowledge that as no 
association between ischaemic stroke and AF was described, we would not expect warfarin to 
be protective. However, the absence of any influence of warfarin on stroke risk remains 
notable. Specifically, warfarin use did not increase hemorrhagic stroke risk. Finally, 
important data were not available from this study which could support our lack of findings 
regarding atrial fibrillation. For example the absence of echocardiography prevents reporting 
of structural abnormalities which may be relevant and absence of INR reporting prevents 
comment about the time in therapeutic range.  
 
Conclusions 
In summary we have shown that in a high risk population of ESRD patients on HD the 
incidence of stroke is high with associated poor outcomes. Presence of AF is associated with 
mortality but we did not detect an association between AF and stroke in this cohort. Neither 
stroke risk nor mortality are altered by warfarin use in this study.  We have described a higher 
incidence of new onset stroke in the incident HD population compared to the prevalent  
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Legend 
 
Figure 1  
Kaplan Meier survival curve of time to stroke in all period-prevalent HD patients with and 
without AF 
 
Figure 2 
Kaplan Meier survival curve of time to stroke in all period-prevalent HD patients with AF 
comparing warfarin or no warfarin users 
 
Table 1 
Stroke vs no stroke, ischemic stroke and hemorrhagic stroke during follow-up 
Table 2  
Stepwise regression of Cox PH model with and without prior cerebrovascular disease 
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Table 1 Stroke vs no stroke. The following non-significant values have been removed: Pre –
dialysis potassium, adjusted serum calcium, ultrafiltration volume, post-dialysis blood 
pressure. Abbreviations: IS = ischemic stroke, HS=hemorrhagic stroke, AF= atrial 
 
Variable 
 
No stroke 
follow up 
 
Stroke 
during 
follow up 
 
p 
 
IS 
 
HS 
p 
(IS vs. 
no 
stroke) 
 1222(88.4) 160(11.6) - 152(11.0) 8(0.6)  
Male(%) 726(59.4) 83(51.9) 0.069 77(50.7) 6(75) 0.04 
 
Age at starting 
RRT(years) 
 
59.9±16.7 
 
65.7±14.3 
 
<0.001 
 
66.3±14.2 
 
54.4±14 
 
<0.001 
 
Race(%) 
White 
Black 
South Asian 
Other 
 
 
1125 (92.0) 
6(0.5) 
79(6.5) 
12(1.0) 
 
 
155(96.9) 
0(0) 
5(3.1) 
0(0) 
 
 
0.151 
 
 
148(97.4) 
0(0) 
4(2.6) 
0(0) 
 
 
7(87.5) 
0(0) 
1(12.5) 
0(0) 
 
 
0.12 
 
Incident patients(%) 
 
731(59.8) 
 
90(56.3) 
 
0.387 
 
88(57.9) 
 
2(25) 
 
0.65 
 
Dialysis vintage*  
(median days and 
IQR) 
 
1248(2344) 
 
1080(1286) 
 
0.075 
 
1046(1286) 
 
1268(1330) 
 
0.08 
 
Diabetes(%) 
 
331(27.1) 
 
57(35.6) 
 
0.024 
 
56(36.8) 
 
1(12.5) 
 
0.01 
AF(%) 256(20.9) 37(23.1) 0.527 36(23.7) 1(12.5) 0.44 
Previous CVD(%) 284(23.2) 43(26.9) 0.309 42(27.6) 1(12.5) 0.23 
Previous CeVD(%) 30(2.5) 21(13.1) <0.001 21(13.8) 0(0) <0.001 
Warfarin(%) 203(16.6) 36(22.5) 0.064 35(23.0) 1(12.5) 0.05 
Antiplatelet(%) 958(78.4) 133(83.1) 0.168 128(84.2) 5(62.5) 0.10 
Hemoglobin(g/dL) 11.1±1.6 11.0±1.7 0.804 11.0±1.6 10.4±1.9 0.99 
Albumin(g/L) 33±6 33±5.0 0.69 33±5 33±7 0.68 
Urea reduction ratio 72±8 72±8 0.863 72±8 74±7 0.99 
Post dialysis 
K(mmol/L) 
3.5±0.5 3.6±0.5 0.041 3.6±0.5 3.4±0.5 0.03 
Pre-dialysis 
PO4(mmol/L) 
1.64±0.57 1.65±0.47 0.856 1.65±0.47 1.75±0.52 0.95 
Pre-dialysis 
SBP(mmHg) 
143±26 145±29 0.282 146±30 135±24 0.21 
Pre-dialysis 
DBP(mmHg) 
74±15 70±16 0.007 70±16 71±18 0.01 
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fibrillation, RRT = renal replacement therapy, CVD=cardiovascular disease, 
CeVD=cerebrovascular disease, K= serum potassium, PO4=serum phosphate, SBP=systolic 
blood pressure, DBP=diastolic blood pressure. *Prevalent patients only
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Model 1 
Variable HR 95% HR Confidence Limits p-value 
Previous CeVD 4.5 2.7 7.3 <0.0001 
Age at starting RRT(y) 1.0 1.0 1.1 <0.0001 
Post dialysis K(mmol/L) 1.3 0.9 1.7 0.13 
Diabetes 1.5 1.0 2.1 0.04 
Model 2 
Variable HR 95% HR Confidence Limits p-value 
Age at starting RRT(y) 1.0 1.0 1.05 <0.0001 
Post dialysis K(mmol/L) 1.3 0.99 1.8 0.06 
Diabetes 1.6 1.1 2.2 0.01 
 
Table 2: Stepwise Cox proportional hazards regression looking at time to stroke, 
n=1121. The following non-significant (p>0.05) covariates were removed; prior 
cardiovascular disease, atrial fibrillation, use of warfarin or antiplatelet therapy, serum 
albumin, calcium, phosphate, blood haemoglobin, pre dialysis systolic blood pressure, 
ultrafiltration volume urea reduction ratio and incident haemodialysis status. Post HD 
potassium was retained as it was of clinical interest. Using these four variables 
generated model 1 where previous CeVD, age at starting RRT and diabetes are 
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significant associations. Removing previous CeVD from the analysis (model 2) retains 
age and diabetes only. 
 
 


SUPPLEMENTAL MATERIAL 
 Age-specific Incidence rate per 100 000 (95% CI) 
Age (y) 
Population at risk   
n 
All HD patients 
(n=1382) 
  
n 
Female 
(n = 573) 
  
n 
Male 
(n=809) 
 
Male 
 
Female 
            
<25 14 11  0 0  0 0  0 0 
25-34 20 17  2 2304.3 (585.6 – 9067.0)  2 5793.9 (1509.3 - 22241.8)  0 0 
35-44 91 46  9 2209.1 (1157.8 - 4215.1)  2 1619.6 (409.7 - 6403.4)  7 2465.5 (1186.3 - 5124.4) 
45-54 122 72  13 2375.2 (1388.2 – 4064.1)  7 3366.7 (1625.3 - 6973.8)  6 1767.8 (799.9 - 3907.1) 
55-64 159 94  30 4476.0 (3155.0 – 6350.1)  10 3963.0 (2159.0 -7274.7)  20 4785.7 (3120.5 - 7339.6) 
65-74 208 170  52 5139.9 (3944.4 – 6697.6)  22 4589.5 (3051.4 - 6902.9)  30 5635.3 (3980.7 - 7977.8) 
75-84 169 143  45 7141.0 (5388.7 – 9463.2)  28 9305.1 (6539.2 - 13240.8)  17 5163.2 (3249.9 - 8202.9) 
>85 26 20  9 11864.3 (6424.9 – 21908.5)  6 28662.0 (14581.4 - 56339.7)  3 5462.1 (1817.7 - 16413.2) 
All ages 809 573  160 4595.0 (3949.6 – 5345.8)  77 5363.4 (4315.9 - 6665.1)  83 4055.8 (3285.2 - 5007.2) 
Standardised rate 
   
1816.8 (1535.3-2098.3) 
  
2478.8 (1925.1 – 3032.4) 
  
1387.5 (1089.0-1686.0) 
 
 
(1) Table I) Incidence rates of stroke (first-ever and recurrent) of hemodialysis study population. Age standardisation with the WHO world 
standard population distribution, based on world average population between 2000-2025 (Ahmad et al, 2001) was performed by the direct method.  
 
 
SUPPLEMENTAL MATERIAL 
 Age-specific Incidence rate per 100 000 (95% CI) 
Age (y) 
Population at risk   
n 
All HD patients 
(n=1331) 
  
n 
Female 
(n = 555) 
  
n 
Male 
(n=776) 
 
Male 
 
Female 
            
<25 14 11  0 0  0 0  0 0 
25-34 20 17  2 2304.3 (585.6 - 9067.0)  2 5793.9 (1509.3 - 22241.8)  2 0 
35-44 90 45  7 1744.0 (836.8 - 3634.6)  1 816.7 (116.0 - 5751.5)  1 2151.1 (974.8 - 4746.9) 
45-54 119 71  10 1883.8 (1019.5 - 3480.6)  6 2963.9 (1347.6 - 6518.9)  6 1218.0 (459.9 - 3225.8) 
55-64 143 94  25 3935 (2679.7 - 5778.3)  10 3963.0 (2159.0 - 7274.7)  10 3916.5 (2384.9 - 6431.8) 
65-74 200 162  47 4774.8 (3612.4 - 6311.3)  20 4285.0(2791.5 - 6580.5)  20 5215.5 (3612.5 - 7529.8) 
75-84 165 136  40 6582.8 (4879.0 - 8881.6)  24 8479.6 (5783.0- 12433.6)  24 4928.9 (3056.8 - 7947.8) 
>85 25 19  8 10967.2 (5703.4 - 21089.3)  5 25099.6(11754.8 - 53594.3) 
 
 5 5657.8(1885.0 - 16982.0) 
All ages 776 555  139 4122.4 (3503.1- 4851.1)  68 4865.7 (3858.9 - 6135.2)  68 3596.1 (2861.9- 4518.8) 
Standardised rate 
   
1614 (1345.7 – 1882.3) 
  
2264.3 (1726.1 – 2802.5) 
  
1183.5 (908.2 -1458.8) 
 
 
(2) Table II) Incidence rates of first –ever stroke in the study group. Age standardisation with the WHO world standard population distribution, based 
on world average population between 2000-2025 (Ahmad et al, 2001) was performed by the direct method.  
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Figure I) Presence of atrial fibrillation and effect on survival, all hemodialysis patients.  
